India, Feb. 27 -- Teleflex (TFX) announced its Board has authorized management to pursue a plan to separate the companys Urology, Acute Care, and OEM businesses into a new, independent, publicly traded company, or NewCo, via a distribution of newly issued shares of NewCo to shareholders. Teleflex RemainCo will consist of Teleflexs Vascular Access, Interventional, and Surgical businesses. Teleflex expects the transaction to be completed mid-2026.
The transaction is expected to be accretive to EPS growth, with RemainCo anticipated to deliver double digit EPS growth in the first full year following the separation. Liam Kelly will continue to lead RemainCo as Chairman, President and CEO. RemainCo will have a simplified operating model with a s...